6-脱氧-6-[18F]氟-L-抗坏血酸PET/CT在术后转移性分化型甲状腺癌中的应用:与氟-18氟代脱氧葡萄糖的对比研究
回顾性纳入2023年9月至2024年5月临床疑似或确诊的术后转移性分化型甲状腺癌患者85例,比较[18F]FAA与[18F]FDG PET/CT的诊断效能。对于颈部淋巴结,[18F]FAA的敏感度(88% vs. 67%)、准确率(82% vs. 69%)和阴性预测值(78% vs. 57%)均优于[18F]FDG(均p < 0.001),特异度(72% vs. 74%,p = 0.64)和阳性预测值(84% vs. 81%,p = 0.44)与[18F]FDG相当。对于远处转移,[18F]FAA对肺转移(53% vs. 27%)和骨转移(72% vs. 21%)的敏感度均高于[18F]FDG(均p < 0.001)。结论认为[18F]FAA PET/CT在显示转移性甲状腺癌方面优于[18F]FDG PET/CT,尤其在颈部淋巴结、肺和骨转移方面。
要点
- [18F]FAA PET/CT对颈部淋巴结转移的敏感度、准确率和阴性预测值均优于[18F]FDG(均p < 0.001)。
- [18F]FAA对肺转移和骨转移的敏感度分别为53%和72%,均高于[18F]FDG的27%和21%(均p < 0.001)。
- [18F]FAA在颈部淋巴结、肺和骨转移中的SUVmax均高于[18F]FDG(均p < 0.01)。
核心结论
- [18F]FAA PET/CT在显示转移性甲状腺癌方面优于[18F]FDG PET/CT,尤其在颈部淋巴结、肺和骨转移方面。
研究设计与样本
- 回顾性研究,纳入2023年9月至2024年5月临床疑似或确诊的术后转移性分化型甲状腺癌患者85例(中位年龄51岁;IQR 38-61岁;女性45例),以组织病理学结果和临床随访作为最终诊断参考标准。
诊断标准与关键数值
- 颈部淋巴结:18F-FAA敏感度88%、准确率82%、阴性预测值78%,18F-FDG分别为67%、69%、57%(均p < 0.001);18F-FAA特异度72%、阳性预测值84%,18F-FDG分别为74%、81%(p = 0.64和p = 0.44)。
- 肺转移:18F-FAA敏感度53%,18F-FDG敏感度27%(p < 0.001)。
- 骨转移:18F-FAA敏感度72%,18F-FDG敏感度21%(p < 0.001)。
- 半定量:18F-FAA在颈部淋巴结转移(10.3 vs. 5.4)、肺转移(4.7 vs. 2.8)和骨转移(16.1 vs. 3.0)中的SUVmax均高于18F-FDG(均p < 0.01);18F-FAA在颈部淋巴结(18.1 vs. 6.8)和骨转移(6.9 vs. 1.9)中的TBR均高于18F-FDG(均p < 0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic performance of ¹⁸F-fluoro-L-ascorbic acid ([¹⁸F]FAA) positron emission tomography-computed tomography (PET/CT) in detecting metastatic differentiated thyroid cancer (DTC) and compare it with ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG) PET/CT.
MATERIALS AND METHODS: Data were retrospectively collected from patients who were clinically suspected or diagnosed with postoperative metastatic DTC between September 2023 and May 2024. Quantification was performed using the maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR). Histopathological outcomes and clinical follow-up served as the reference standard for final diagnosis. Diagnostic accuracy was compared using McNemar's test, and tracer uptake was analyzed via the Wilcoxon signed-rank test.
RESULTS: A total of 85 participants (median age, 51 years; IQR, 38-61 years; 45 women) were evaluated. For cervical lymph nodes (LNs), [¹⁸F]FAA showed superior sensitivity (88% vs. 67%), accuracy (82% vs. 69%), and negative predictive value (78% vs. 57%) (all p < 0.001), with comparable specificity (72% vs. 74%, p = 0.64) and positive predictive value (84% vs. 81%; p = 0.44) than [18F]FDG. For distant metastases, [¹⁸F]FAA PET/CT demonstrated higher sensitivity than [¹⁸F]FDG for pulmonary metastases (53% vs. 27%), and bone metastases (72% vs. 21%) (all p < 0.001). Semiquantitatively, [¹⁸F]FAA had higher SUVmax in the cervical LN metastasis (10.3 vs. 5.4), pulmonary metastasis (4.7 vs. 2.8), and bone metastasis (16.1 vs. 3.0), as well as higher TBR in cervical LN (18.1 vs. 6.8) and bone metastasis (6.9 vs. 1.9) (all p < 0.01).
CONCLUSION: [18F]FAA PET/CT outperforms [18F]FDG PET/CT in the depiction of metastatic thyroid cancer, particularly in neck LNs, pulmonary, and bone metastases.
KEY POINTS: Question Is 6-Deoxy-6-[18F]fluoro-L-ascorbic acid PET/CT ([18F]FAA) PET/CT an imaging method that can identify metastatic lesions after thyroid cancer surgery, and is it superior to [18F]FDG PET/CT? Findings [¹⁸F]FAA exhibited higher sensitivity and elevated SUVmax values compared to [¹⁸F]FDG in the detection of lymph node, lung, and bone metastases of metastatic thyroid cancer. Clinical relevance [¹⁸F]FAA is a reliable diagnostic tool that can accurately locate metastatic sites after thyroid cancer surgery. This helps tailor treatment plans and predict prognosis based on different metastatic scenarios.
引用
- Yang T, Ge S, Chen Z, et al. 6-Deoxy-6-[18F]fluoro-L-ascorbic acid PET/CT in postoperative metastatic differentiated thyroid cancer: a comparative study with fluorine-18 fluorodeoxyglucose. Eur Radiol. 2025. PMID: 41176553. doi:10.1007/s00330-025-12092-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。